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Abstract: Glycopeptide antibiotics 
such as vancomycin and teicoplanin are 
used to treat life-threatening infections 
caused by multi-drug-resistant Gram-
positive pathogens. They inhibit 
bacterial cell wall biosynthesis by 
binding to the D-Ala-D-Ala C-terminus 
of peptidoglycan precursors. 
Vancomycin resistant bacteria replace 
the dipeptide with the D-Ala-D-Lac 
depsipeptide, thus reducing the binding 
affinity of the antibiotics with their 
molecular targets. Herein, we report on 
our studies of the interaction of 
teicoplanin, teicoplanin-like A40926, 
and of their semi-synthetic derivatives 
(mideplanin, MDL63,246, dalbavancin) 
with peptide analogues of cell wall 
precursors by NMR spectroscopy and 
surface plasmon resonance (SPR). 
NMR revealed the existence of two 
different complexes in solution, when 
the different glycopeptides interact with 
Ac2KDAlaDAlaOH. Despite the NMR 
experimental conditions, which are 
different from those employed for the 
SPR measurements, the NMR results 
parallel those deduced in the chip 
regarding the drastic binding difference 
existing between the D-Ala and the D-
Lac terminating analogues, confirming 
that all these antibiotics share the same 
primary molecular mechanism of action 
and resistance. The kinetic analysis of 
the interaction between the 
glycopeptide antibiotics and 
immobilized AcKDAlaDAlaOH by SPR 
suggest a dimerization process, that was 
not observed by NMR in DMSO 
solution. Moreover in SPR, all the 
glycopeptides with a hydrophobic acyl 
chain present stronger binding with a 
hydrophobic surface than vancomycin, 
indicating that additional interactions 
through the employed surface are 
involved. Concluding, SPR provide 
tools to differentiate between 
vancomycin and other glycopeptides 
and the calculated binding affinities at 
the surface seem to be more relevant to 
in vitro antimicrobial activity than the 
estimations from NMR analysis. 
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Introduction 
Glycopeptide antibiotics such as vancomycin and teicoplanin are 
frequently used to treat life-threatening infections caused by multi-
drug-resistant Gram-positive pathogens. They are drugs of last 
resort against multi-resistant methicillin-resistant Staphylococcus 
aureus (MRSA), which is nowadays a major cause of community-
acquired infections and determines high morbidity and mortality 
rates in hospital-acquired infections.[1] Vancomycin and teicoplanin 
are in clinical use since 1958 and 1988, respectively. The spread of 
resistance to glycopeptides in enterococci since 1988 and the recent 
emergence of high level of glycopeptide resistance in clinical 
isolates of MRSA have prompted the search for second-generation 
drugs belonging to this chemical class.[2] 
This glycopeptide family is composed of heptapeptides, 
oxidatively linked among aromatic amino acids and decorated with 
chlorine atoms, glycosidic moieties, and (in the case of teicoplanin 
and teicoplanin-like molecules) lipid chains. These complex 
molecules inhibit bacterial cell wall synthesis by binding to the 
[a] M.J., Hernáiz,* J., Treviño, C., Bayón 
Departamento de Química Orgánica y Farmacéutica 
Universidad Complutense de Madrid 
Pz/ Ramón y Cajal s/n. 28040 Madrid. Spain 
Tel: (+) 34 91139 41821; Fax: (+) 34 9139 41822 
Email: mjhernai@ucm.es 
[b] J., Jiménez-Barbero, A., Ardá 
Chemical and Physical Biology,  
Centro de Investigaciones Biológicas, CSIC 
Ramiro de Maeztu 9, 28040 Madrid. Spain. 
[c] F., Marinelli 
Dipartimento di Biotecnologie e Scienze della Vita 
Università degli Studi dell’Insubria 
Via J. H. Dunant 3, Varese 21100, Italy 
[d] F., Marinelli 
The Protein Factory” Research Center 
Politecnico of Milano, ICRM CNR Milano and University 
of Insubria. Varese, Italy  
[e] R., Gandolfi 
Dipartimento di Scienze Farmaceutiche, Università degli 
Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy  
[f] F., Molinari, 
 Department of Food, Environmental and Nutritional 
Sciences (DeFENS), University of Milan, Via 
Mangiagalli 25, 20133 Milano, Italy 
 
Supporting information for this article is available on the WWW 
under http://www.chemeurj.org/ or from the author. 
 2 
dipeptide terminus D-Ala-D-Ala of the peptidoglycan (PG) 
precursors[3], sequestering the substrate from transpeptidation and 
transglycosylation reactions in the late extracellular stages of PG 
cross-linking (Fig.1). The D-Ala-D-Ala complex with vancomycin is 
stabilized by an array of hydrophobic van der Waals contacts and 
five hydrogen bonds (H-bonds) lining the antibiotic binding pocket 
(Fig. 2).[4] Bacteria resistant to glycopeptides remodel their PG 
precursor terminus from D-Ala-D-Ala to D-Ala-D-Lac.[5] The 
substitution of the initial amide moiety in D-Ala-D-Ala by an ester 
linkage in D-Ala-D-Lac strikingly reduces the binding (in aqueous 
solution) to vancomycin by 1000-fold and renders the antibiotic 
therapeutically useless.[5-6] The complex of vancomycin with D-Ala-
D-Lac lacks the central H-bond and suffers of a repulsive lone pair 
interaction between the vancomycin residue 4 carbonyl and D-Ala-
D-Lac ester oxygens (Fig.2). 
 
Figure 1. Schematic view of peptidoglycan structure and mechanism of action of 
glycopeptide antibiotics. Glycopeptides inhibit transglycosylation and transpeptidation 
by binding to the C-terminal D-Ala-D-Ala of the late PG precursors. (A) Vancomycin-
type glycopeptide activity is based on dimerization, which enhances binding to the 
target peptide through both cooperative and allosteric effects. (B) Lipoglycopeptides 
(e.g. teicoplanin and its derivatives) have a fatty acyl chain anchored in the 
phospholipid bilayer that enhances the binding affinity to the target. 
Previous NMR and X-ray studies[7] have indicated that 
vancomycin and similar natural products such as eremomycin have 
the ability to dimerize in aqueous solution, and that dimerization 
plays an important role in their biological activity. Surface Plasmon 
Resonance (SPR) has been also used to study the interaction 
between vancomycin (and related eremomycin, cloroeremomycin, 
balhimacyn) and tripeptide analogues of PG precursors terminating 
in D-Ala-D-Ala and D-Ala-D-Lac in lipid bilayers[8] and self 
assembled monolayers.[9]  
Crystal structure of the complexes teicoplanin-D-Ala-D-Ala and 
dalbavacin-D-Ala-D-Ala (a semi synthetic derivative) have been 
recently described, showing that the interaction of these 
lipoglycopeptides with the dipeptide is produced forming the same 
hydrogen bonds than vancomycin (Fig.2).[10] For teicoplanin 
deglycosylated derivatives, no evidence of dimer formation at 
millimolar concentrations was reported in past studies[11], but the 
teicoplanin’s lipid chain, (an extra aliphatic acyl side chain on 
glucosamine at residue 4) which is absent in vancomycin-like 
molecules, anchors the antibiotic to the lipid layer of the bacterial 
membrane[7b]. Lipoglycopeptides such as teicoplanin and its 
derivatives are reported to be more effective than vancomycin 
against Gram-positive cocci[12]. As a consequence, most of the 
second generation semi-synthetic glycopeptides have been prepared 
introducing hydrophobic moieties in the heptapeptide scaffold in 
order to confer increased membrane anchoring ability, which could 
conceivably lead to increased binding to PG terminus[2b, 13]. 
 
Figure 2. Schematic view of the key intermolecular hydrogen bonds described for 
vancomycin (pdb code 1FVM) and ligand terminating in D-Ala-D-Ala and kept for the 
molecular mechanics calculations of the different complexes studied herein. Chemical 
shift perturbations at w2 of the antibiotic and at the two methyl groups of the three-
peptide were monitored to proof the existence of stable binding. 
The aim of this study is to investigate the interaction of 
teicoplanin, teicoplanin-like A40926[14], and the semi synthetic 
derivatives mideplanin[15], MDL63,246[16], dalbavancin[15, 17] with 
peptide analogues of cell wall precursors by NMR and SPR 
spectroscopy, being the latter an adequate system to predict 
biological activity. It is worth noting that dalbavancin is currently 
completing phase III clinical trials to treat acute bacterial skin and 
skin structure infections caused by susceptible Gram-positive 
bacteria (http://www.duratatherapeutics.com/). These studies may be 
also useful in the recent efforts to redesign glycopeptide antibiotics 
for the treatment of resistant microbial infections, including MRSA, 
and examine their future potential for providing a new class of 
antibiotics less prone to bacterial resistance. 
Results and Discussion 
NMR studies were performed to analyze the molecular recognition 
behavior of the different glycopeptides versus D-Ala-D-Ala and D-
Ala-D-Lac terminating peptides. In particular, the interaction of the 
glycopeptide antibiotics mideplanin, teicoplanin, dalbavancin, 
A40926 and MDL63,246 (Fig. 3) with the PG precursor analogues  
Ac2KDAlaDAlaOH and Ac2KDAlaDLac acid was monitored.  
 The obtained data will be presented in detail for teicoplanin. 
Nevertheless, analogous conclusions were deduced for all the 
studied glycopeptides. In all cases, no evidences of glycopeptide 
dimerization were inferred under these experimental conditions, 
especially from the DOSY experiments (see below). 
Nuclear Magnetic Resonance: teicoplanin model 
Previous works[18] have focused on the solution conformation of 
teicoplanin as well as on its interactions with the di- and three-
peptide PG precursor models. These previous works have been 
performed mostly on the aglycone (devoid of all the sugar moieties 
and consequently of the lipid chain) or pseudoaglycone (devoid of 
some sugar moieties and of the lipid chian) derivatives of 
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teicoplanin in a variety of solvents, trying to overcome the solubility 
problems inherent to some of these molecules[18]. All the molecules 
studied herein display a lipid chain attached at the glucosamine 
moiety and therefore their solubility in water is basically negligible. 
Thus, the NMR experiments were performed in dimethyl sulfoxide 
(DMSO). As mentioned in the experimental section, there are two 
key structural reporter evidences that permit to monitor the 
existence (or not) of stable intermolecular complexes between the 
antibiotics and the PG precursor Ac2KDAlaDAlaOH. Thus, 
chemical shift perturbations at w2 (Fig. 2) of the antibiotic and at 
the two methyl groups of the tripeptide were monitored to proof the 
existence of the molecular recognition process.[4, 19] 
 
Figure 3. Structures of glycopeptide antibiotics used in this study. Teicoplanin and 
A40926 are natural microbial products[20]. Mideplanin and dalbavancin are the 
dimethylaminopropyl amide of teicoplanin and A40926, respectively[15]. MDL63,246 
differs from dalbavancin for the reduction to alcohol of the carboxyl group in the N–
acylglucuronic moiety.. 
For teicoplanin, the chemical shift of the w2 proton was 
identified through its TOCSY crosspeak to the corresponding Ha 
(7.45/4.85), and found to be similar to that previously reported 
(7.41/4.97).[18] 
Fittingly, when Ac2KDAla DAlaOH (3mM) was added to the 
NMR tube containing 2 mM teicoplanin, the existence of drastic 
chemical shift changes for several protons was evident. Interestingly, 
a new broad NH signal appeared, at very low field, at ca. 13 ppm. 
This NH displayed a broad TOCSY cross peak with one Ha at 5.02 
ppm (see Fig. S1 in supporting information), indicating that the w2 
NH is perturbed in more than 5 ppm when teicoplanin forms the 
complex with Ac2KDAlaDAlaOH. The corresponding signal was 
found to be rather broad, splitted into two signals, permitting 
distinction of a major and a minor peak, and thus suggesting the 
existence of two different (although structurally similar) bound 
species.  
From the Ac2KDAlaDAlaOH viewpoint, a new signal at high 
field (0.46 ppm) appeared. In the ROESY spectrum, it can be seen 
that this signal shows a chemical exchange crosspeak with one of 
the methyl resonances of the free species at 1.28 ppm (Fig. 4). 
Therefore, this signal can be readily identified as belonging to Ala-3 
moiety. The important shielding (more than 0.8 ppm) of this methyl 
group suggests that, in the complex, it is surrounded by one or more 
of the aromatic rings of the antibiotic. Additional exchange cross 
peaks were found for the NH protons of Ala-2 and Ala-3 residues 
which were deshielded in ca. 0.7 and 0.3 ppm, respectively. Again, 
there was indication of the existence of one major and one minor 
species, accounting for the existence of two very similar bound 
species (as demonstrated in Fig. S1 in supporting information). 
 
Figure 4. ROESY spectrum of the mixture of teicoplanin/Ac2KDAlaDAlaOH (1/1.5 
molar ratio). The circled areas highlight chemical exchange cross peaks corresponding 
to the Ala-3 methyl group (high field) and the Ala NHs (low field) between its free and 
antibiotic-bound forms, as discussed in the text.  
Additional indication of the existence of interaction came from 
the analysis of DOSY spectra (Fig. 5). The comparison of the 
diffusion coefficients measured for free Ac2KDAlaDAlaOH and in 
the presence of teicoplanin (teicoplanin/Ac2KDAlaDAlaOH in 1/1.5 
molar ratio) indicated that the mixture showed an apparent diffusion 
coefficient significantly higher (ca. 0.4 units in log D) than that of 
free Ac2KDAlaDAlaOH. Thus, this experiment provided an 
additional indication of the existence of a strong intermolecular 
interaction between both species. No changes in the diffusion 
coefficient for the glycopeptide itself was observed in the presence 
of Ac2KDAlaDAlaOH, strongly suggesting that teicoplanin remains 
as monomer in DMSO solution even in the presence of the PG 
model peptide. Thus, according to these NMR experimental data, 
the existence of a molecular complex can be granted. The chemical 
shift data suggests that, very probably, the geometry already 
described for this family of antibiotics is indeed that present in 
DMSO solution. A 3D view of the complex will be presented below.  
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Figure 5. DOSY spectra: black: free teicoplanin; blue: teicoplanin+Ac2KDAlaDAlaOH; 
red: Ac2KDAlaDAlaOH. 
In contrast, when Ac2KDAlaDLac acid (3 mM) was added to the 
NMR tube containing teicoplanin, only very minor chemical shift 
changes in some protons of teicoplanin and of Ac2KDAlaDLac acid 
were evident. Importantly, no protons at either low (ca. 12 ppm) or 
high (ca. 0.46 ppm) field were detected. Moreover, when the DOSY 
were compared, now the same apparent diffusion coefficients were 
observed both for free Ac2KDAlaDLac acid and for this compound 
in the presence of teicoplanin. These results indicate that, for this 
ligand, the interaction with teicoplanin is much weaker than that 
described above for Ac2KDAlaDAlaOH. 
The 3D structure of the formed complexes was derived using 
molecular modelling methods, as described in the experimental 
section. The combination of docking protocols, molecular 
mechanics and molecular dynamics calculations provided different 
solutions to the structure of the complex. The most stable one 
formed between teicoplanin and Ac2KDAlaDAlaOH is displayed in 
Fig. 6, and is in agreement with those previously proposed for a 
variety of antibiotic-PG precursor analogue pairs[18]. In any case, a 
second ligand conformation was also detected, with a relative 
energy about 2 kcal/mol above that of the global minimum. Herein, 
a hydrogen bond between the phenolic ring of 3 and the carbonyl 
group of the acetyl group of the Lys moiety (K) takes place. This 
acetyl group is in turn hydrogen bonded to the NH group of Ala-2. 
This structural pattern (see Fig. S2 in supporting information) 
replaces the most stable one formed by the amide nitrogen of 5 and 
the carbonyl oxygen of Lys (Fig. 2 and Fig. 6). Both types of 
complexes comply with the experimental NMR data described 
above, since both maintain the hydrogen bond pattern as well as the 
stacking interaction of the Ala-3 methyl group. Recently, the X-ray 
structures of different teicoplanin analogues complexed with 
bacterial cell-wall peptides, using either MBP or ubiquitin as ligand 
carrier have been reported [10a]. The obtained structures (pdb codes 
3VFJ and 3VFK) were strikingly similar to the major conformer 
presented herein. 
In contrast, for the Ac2KDAlaDLac acid analogue, after the MD 
protocol, no intermolecular complex was evident (Fig. 7). The 
Ac2KDAlaDLac acid molecule dissociated from the teicoplanin 
binding site, indicating that the hydrogen bonds involving the 
carboxylate moiety were not strong enough to keep this molecule 
attached to teicoplanin. Indeed, after molecular mechanics 
optimization, the obtained structure was ca. 10 kJ/mol less stable 
than that obtained for the teicoplanin/Ac2KDAlaDAlaOH complex. 
Nuclear Magnetic Resonance: teicoplanin family derivatives 
Analogously, NMR experiments were performed to monitor the 
molecular recognition features of a variety of glycopeptide 
antibiotics with Ac2KDAlaDAlaOH and its lactic acid analogue. In 
particular, the interaction of these two tripeptides with mideplanin, 
MDL63,246, dalbavancin, and A40926 was monitored using 
chemical shift perturbation data and DOSY experiments. 
The NMR experiments indicated the existence of interactions 
between the antibiotics and Ac2KDAlaDAlaOH in all cases and the 
acquired spectra are very similar to those presented in Figures 4 and 
5 for teicoplanin. Similar features were always observed, including 
the presence of one very major and one minor bound species. 
Shielding of the methyl group of Ala-3 upon binding to the 
antibiotic was observed, together with the presence of a chemical 
exchange process which is slow in the chemical shift timescale. The 
antibiotic-complexed Ala-3 methyl group appeared always around 
0.45 ppm, indicating a similar recognition motif in all cases. 
Moreover, deshielding of the w2 NH of MDL63,246, A40926, 
mideplanin, and dalbavancin in the presence of Ac2KDAlaDAlaOH 
was evident. The NH corresponding to the bound species appeared 
between 12 and 13 ppm. Besides, the change in the diffusion 
coefficient of Ac2KDAlaDAlaOH was always significant, varying in 
0.3-0.4 units in log D value. These data indicate that, in all cases, 
there is a strong interaction between Ac2KDAlaDAlaOH and all the 
antibiotics, and suggest that, in solution, at the atomic level, the 
recognition features of MDL63,246, A40926, teicoplanin, 
mideplanin, and dalbavacin are fairly similar. Fittingly, our global 
minima structures are also very similar to the X-ray crystallographic 
structure recently obtained for dalbavancin using a carrier protein 
strategy [10b]. 
 
 
Figure 6. The complex formed between teicoplanin and the Ac2KDAlaDAlaOH peptide according to molecular modeling. Left, the global minimum structure (the 
Ac2KDAlaDAlaOH is in ball and sticks representation) after MD (1 ns) simulations followed by energy minimization. The key hydrogen bonds are indicated. These hydrogen bonds 
(three involving the carboxylate group of Ala-3 and one involving Ala-3 NH) remained for more than 90% of the time during the MD run. One additional hydrogen bond involving 
the CO of Lys-1 was present in the MD for more than 50% of the time. A superimposition of 10 snapshots at different times of the MD simulation is presented in the middle and 
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right panels. The structure of the complex is fairly well defined, with significant motion of the lysine side chain and the N-acyl lipid chain at the glucosamine moiety. The right panel 
highlights the packing of the methyl group of Ala-3 towards one of the aromatic rings of teicoplanin. This orientation perfectly matches with the observed chemical shift perturbation 
data. 
 
Figure 7. The complex formed between teicoplanin and the Ac2KDAlaDLac acid 
analogue (in ball and sticks representation). The key intermolecular interactions present 
in the three-peptide analogue (see above) are destroyed after the MD equilibration 
period. No intermolecular hydrogen bonds are formed and therefore, no complex is 
present in solution. 
A superimposition of the global minima of all complexes 
derived from the molecular modeling protocol is displayed in Figure 
8. 
In contrast, when the Ac2KDAlaDLac acid analogue was 
employed, very minor chemical shifts were evident, no slow 
exchange process took place and no changes in the diffusion 
coefficient of the ligand were observed. Therefore, these 
experimental evidences strongly indicate that the interaction of the 
lactic acid terminating analogue with the tested antibiotics is rather 
weak. 
Surface Plasmon Resonance Studies 
 
The interaction of the glycopeptide antibiotics mideplanin, 
teicoplanin, dalbavancin, A40926 and MDL63,246 (Fig. 3) with PG 
precursor analogues AcKDAlaDAlaOH and AcKDAlaDLac acid 
immobilized on the surface were also analyzed in SPR by firstly 
using the CM5 sensor chip. Vancomycin was used a control. 
Sensograms registering the binding of the glycopeptides to 
AcKDAlaDAlaOH surface showed mass transport limitations that 
could be likely caused by a excessive ligand density on this surface 
(see Fig. S3 in supporting information). To elude this problem a 
CM4 chip, with a lower degree of carboxymethylation, was 
prepared to obtain less ligand density. Binding responses of each 
glycopeptide antibiotic with AcKDAlaDAlaOH in chip CM4 are 
shown in Fig 9. Binding responses were fit to a bivalent interaction 
model[21]. This mechanism could be consistent with dimerization of 
the glycopeptide molecules at the surface, enhanced in the presence 
of the ligand[22]. This effect might explain the association signals 
obtained, which exhibit an initial increase in response to the binding 
of one glycopeptide molecule to an AcKDAlaDAlaOH molecule in 
the surface and a subsequent less steeped slope associated with the 
binding of a second glycopeptide molecule due to surface 
dimerization. On the other hand, dissociation profiles show a first 
rapid phase and a slower second phase that would be due to the fact 
that binding between the dimerized glycopeptides and 
AcKDAlaDAlaOH in surface being stronger. Binding constants are 
provided in Table 1. None of the glycopeptides produced detectable 
binding signals in the AcKDAlaDLac acid surface, confirming the 
NMR data on the weakness of interaction with the PG precursor 
analogue terminating with the depsipeptide. SPR identical results 
were obtained using the Ac2KDAlaDAlaOH and Ac2KDAlaDLac 
tripeptide analogues used in NMR experiments (data not show), as 
expected considering that the N-terminal region is not involved in 
ligand binding. 
 
Figure 8. Superimposition of the complexes formed between MDL63,246, A40926, 
teicoplanin, mideplanim, and dalbavancin with the three-peptide (in ball and sticks 
representation) according to molecular modeling. The optimization involved MD (1 ns) 
simulations followed by energy minimization. The key hydrogen bonds are present in 
all cases for more than 90% of the time during the MD run. The shapes of the formed 
complexes are fairly similar. Different orientations of the pendant chains of the 
antibiotics as well as motion of the lysine side chain may be appreciated. In contrast, the 
recognition of the D-Ala-D-Ala dipeptide moiety is basically identical in the five cases. 
The dissociation constants KD1 and KD2 calculated as kd1/ka1 and 
kd2/ka2 respectively, were found to be in a nanomolar range. 
Teicoplanin, mideplanin, dalbavancin and MDL63,246 exhibit a 
slightly lower KD1 and KD2, which indicated a stronger binding to 
AcDAlaDAlaOH. In contrast, vancomycin and A40926 exhibit a 
moderate higher KD1 and KD2 indicating lower binding (Table 1). 
 
 
Figure 10.Binding responses (%) of the glycopeptide antibiotics on hydrophobic 
surface (HPA chip)  
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Vancomycin, mideplanin, teicoplanin, dalbavancin, A40926 and 
MDL63,246 were then injected in a hydrophobic surface (HPA 
chip) at 10 µM to analyze the interaction involving lipid chains. 
Responses shown in Fig. 10 suggest that all the glycopeptides 
analyzed presented stronger interaction through the hydrophobic 
surface in comparison with vancomycin. This fact could be 
attributed to the presence of a hydrophobic acyl chain on the 
heptapeptide scaffold, which can be responsible of the anchorage of 
the glycopeptides at the cell membrane.[7b] The stronger interactions 
of semi synthetic derivatives, particularly MDL63,246, may 
correlate with the lower MICs observed for these molecules versus 
coagulase negative staphylococci, streptococci and enterococci.[15-17] 
 
 
 
 
Figure 9. Binding responses of the glycopeptide antibiotics with AcKDAlaDAlaOH immobilized on a CM 4 chip (black lines) showing association and dissociation phases. 
Responses were reference subtracted and blank corrected. Binding responses were fit to a bivalent interaction model. 
Table 1. Binding constants for the glycopeptide – AcKDAlaDAlaOH interactions determined at 25 ºC. 
Glycopeptide ka1  (M-1s-1) kd1 (s-1) ka2  (RU-1s-1) kd2 (s-1) KD1 (nM) KD2 (RU) 
Vancomycin 2.36 (7) × 105 8.2 (2) × 10-1 3.8 (2) × 10-5 4.2 (2) × 10-3 3466 110 
Teicoplanin 5.52 (9) × 105 9.1 (2) × 10-2 6.0 (2) × 10-5 4.1 (1) × 10-3 165 68 
Mideplanin 2.77 (7) × 105 1.06 (2) × 10-1 3.5 (1) × 10-5 2.93 (7) × 10-3 383 83 
Dalbavancin 8.9 (3) × 105 2.9 (1) × 10-1 9.6 (8) × 10-5 7.1 (4) × 10-3 327 74 
A40926 2.42 (5) × 104 2.53 (2) × 10-1 2.06 (7) × 10-6 6.1 (1) × 10-3 10455 2981 
MDL63,246 1.70 (5) × 105 1.21 (2) × 10-1 2.0 (1) × 10-5 4.1 (1) × 10-3 712 200 
Note: numbers between parentheses are standard errors.  
Conclusion 
This work examined the binding of different glycopeptides 
antibiotics (vamcomycin, teicoplanin, teicoplanin-like A40926, 
mideplanin, MDL63,246, dalbavancin) toward two types of cell wall 
precursor analogues (AcKDAlaDAlaOH/Ac2KDAlaDAlaOH and 
AcKDAlaDLac acid/Ac2KDAlaDLac acid) by employing solution 
NMR spectroscopy and SPR methods. In particular, we focused on 
the role of the hydrophobic fatty acid tail, which is considered 
related to the improved antimicrobial activity of teicoplanin and 
analogues against Gram-positive cocci.  
The NMR data were obtained in DMSO solution due to the poor 
solubility of these molecules in water. The analysis of the 
experimentally obtained NMR parameters strongly suggests the 
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existence of two different complexes in solution for the 
glycopeptides when they interact with Ac2KDAlaDAlaOH. 
Although the NMR experimental conditions were markedly 
different to those employed for the SPR measurements, the NMR 
results paralleled those deduced in the chip regarding the drastic 
binding difference existing between the D-Ala and the D-Lac  
terminating analogues, confirming that all these antibiotics share the 
same primary molecular mechanism of action and resistance. In 
other terms structural modifications occurring among natural 
glycopeptides (such as vancomicyn, teicoplanin and A40926) and 
those chemically introduced in the semi-synthetic derivatives do not 
modify their mode of interaction with D-Ala-D-Ala or D-Ala-D-Lac 
termini of PG precursors. The dramatic differences in the antibiotic  
affinity between the tripeptide analogues terminating in D-Ala and 
D-Lac is in agreement with the glycopeptide poor biological activity 
versus vancomycin reistant vanA enterococci and staphylococci, 
that replace D-Ala with D-Lac. 
We showed that SPR is well suited for the real time analysis of 
binding interactions at a model surface and provides tools to 
differentiate between vancomycin, teicoplanin, A40926 and other 
glycopeptides derivatives. Using a hydrophobic surface, it was 
possible to sort out  the existence of a positive effect of the fatty acid 
chain for anchoring the antibiotics at the membrane. The observed 
differences under the SPR experimental conditions indicate that 
additional interactions through the employed surface are involved. 
Thus, the calculated binding affinities at the surface seem to be more 
relevant to in vitro antimicrobial activity than the estimations from 
NMR in DMSO solution.  
Previous data about the absence of dimerization in the NMR 
studies of teicoplanin were confirmed by our data in DMSO solution. 
Considering the crystal structures previously described, which 
demonstrated that the interaction between lipoglycopeptides and cell 
wall precursors are established in the same way than vancomycin,[10], 
analysis by SPR showed that the binding of the glycopeptides to 
AcKDAlaDAlaOH on the surface was fit to a bivalent interaction 
model, which could be consistent with dimerization of the 
glycopeptide molecules. Thus, we provided evidences on the effect 
of cooperative binding of teicoplanin and its derivatives to bacterial 
cell surfaces. Our data suggest that dimerization and membrane 
anchoring are two interaction processes, which may synergically 
contribute to the activity of semi synthetic antibiotics and that can 
be further exploited in the search of better drugs to face resistant 
bacteria. 
Experimental Section 
Materials 
All commercial products were used without any further purification step. 
Ac2KDAlaDAlaOH, AcKDAlaDAlaOH, Ac2KDAlaDLac acid acetate and 
AcKDAlaDLac acid acetate (PG precursor analogues) were purchased from Bachem. 
Vancomycin was purchased from Sigma-Aldrich. SPR sensor chips CM5 
(carboxymethylated dextran), CM4 (low-density carboxymethylated dextran) and HPA 
(flat hydrophobic surface) and others reagents used in SPR experiments were purchased 
from GE Healthcare. All other chemicals were obtained from commercial sources.  
Preparation of Glycopeptides  
A40926 and teicoplanin were prepared by fermentation of the producing strains 
Nonomuraea sp. ATCC 39727 and Actinoplanes teichomyceticus ATCC 31121, 
respectively, as described elsewhere[20]. Mideplanin, MDL63,246 and dalbavancin were 
prepared by chemical modification of teicoplanin and A40926, respectively[15].  
The purity of the glycopeptides was confirmed by HPLC (> 85%) on an HPLC Agilent 
1100 with UV-vis detector using Mediterraneasea 18 15 cm x 0.46 5 mm column 
(Teknokroma). A40926, Dalbavancin, MDL63,246 and mideplanin were analysed using 
the conditions determined by Gandolfi.[23] The solvent system consisted of an aqueous 
solution of trifluoracetic acid (0.1%) and acetonitrile. Teicoplanin was analyzed using 
the analytical method of Borghi[24]. Mobile phase was: A 0.02M NaH2PO4-CH3CN 
(95:5), B 0.02M NaH2PO4-CH3CN (25:75). 
Nuclear Magnetic Resonance  
NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer, equipped with 
a triple channel cryoprobe. Chemical shifts (d) are expressed in parts per million (ppm). 
Two peptides that are PG precursor analogues (Ac2KDAlaDAlaOH and Ac2KDAlaDLac 
acid acetate) were dissolved in DMSO-d6 to obtain 100mM stock solutions and further 
diluted to 3 mM. Glycopeptide antibiotics were dissolved to 2 mM in in DMSO-d6. 
First, standard 1H 1D NMR, 2D ROESY (mixing time 100 ms) and 2D TOCSY 
(mixing time 60 ms) spectra were recorded. Then, the PG precursor analogues were 
added to the NMR tube containing the antibiotic to give a final concentration of 3 mM. 
Therefore, the final antibiotic: ligand molar ratio was 1:1.5. For these samples, 
additional standard 1H 1D NMR, 2D ROESY, and 2D TOCSY experiments, with the 
same mixing times were also acquired. All the experiments were recorded at 298 K. The 
existence of stable complexes was deduced by monitoring the chemical shift 
perturbation induced at the W2 proton (Fig. 2), at the “east side of the macrocyclic 
structure”. When stable complexes are formed, this N-H establishes a strong 
intermolecular hydrogen bond with the carboxylate group of the ligand. Thus, this 
particular proton suffers a drastic downfield shift upon binding. At the same time, and 
from the perspective of the peptide, the methyl groups of the D-Ala-D-Ala moiety suffer 
a significant upfield shift, indicating that they are now located below the aromatic rings 
of the antibiotic.[4] DOSY experiments were also performed to obtain further 
information about the molecular recognition process. Experiments were performed for 
the isolated PG precursor analogues and for their final 1:1.5 samples with the different 
antibiotics. The DOSY spectra were recorded with the double stimulated spin echo 
(dstegp3s) pulse sequence, with convection compensation, with a linear gradient 
between 2% and 95%. Thirty-two 1D 1H spectra were collected with a duration of d = 
1.8 ms and an echo delay of = 250 ms and processed using the standard Bruker software. 
Conformational analysis 
Molecular mechanics calculations for the antibiotics in the presence of the PG precursor 
analogues were performed using Macromodel 9.6, as implemented in the Maestro suite 
of programmes (version 8.5.110). The structures of the antibiotics were built using the 
coordinates for vancomycin, teicoplanin and other related antibiotics complexed to 
different PG precursor analogues deposited in the Protein Data Bank (pdb codes 1FVM, 
1QD8, 2WDX, and 3MG9). The side chains of the different antibiotics were prepared 
from these structures as required. For the modelling the complexes with 
Ac2KDAlaDAlaOH, the starting geometry of the three-peptide in the 1FVM deposit was 
chosen. The Ac2KDAlaDLac analogues were built by simple modification of the 
affected atoms. Then, Ac2KDAlaDAlaOH or Ac2KDAlaDLac were manually docked to 
comply with the experimental intermolecular hydrogen bond pattern extensively 
described (Fig. 2) and the obtained complexes were minimized using the OPLS* force 
field, and a distance-dependence bulk dielectric constant of 70 debyes.  
The minimized complexes were then submitted to 1 ns of MD simulations at 300 K, 
using the same force field, and no intermolecular restraints, to proof the conformational 
stability of the complexes. The equilibration time was 100 ps, the integration step was 
1.5 fs, and the shake protocol was applied to the C-H bonds. In all cases, the 
temperature was stable within 2º. For the Ac2KDAlaDAlaOH complexes, the geometry 
of the complexes were found to be fairly stable during the whole MD run, keeping the 
intermolecular hydrogen bonds for more than 80% of the simulation time. Variations on 
the orientation and hydrogen bond pattern of the C-terminus of the Ac2KDAlaDAlaOH 
complexes were found, while the Ac2KDAlaDLac complexes dissociated after ca. 200 
ps of simulation time, indicating their marginal stability. 
Additionally, alternative geometries for the complexes were deduced by using 
AutoDock 4.2. Atom types and partial charges (Gasteiger-Hückel) for each nucleotide 
were calculated using the Sybyl 8.0 program, and the corresponding data were saved as 
a mol2 file. The starting geometries for the antibiotics were obtained from the Protein 
Data Bank, as described above, and optimized using the protein preparation wizard of 
Macromodel, as integrated in the Maestro package. In particular, after the hydrogen 
atoms were added, the structures were subsequently minimized with the OPLS-2005* 
force field, using Truncated Newton Conjugate Gradients. The ligands (if any) were 
fixed to their crystallographic positions. Then, the ligand was removed from the binding 
pocket and the resulting coordinates were saved as a new pdb file. For those cases with 
several molecules in the crystallographic unit cells, only one of them was considered as 
being rigid, to facilitate the docking process. For the Autodock calculations, grid maps 
(grid spacing: 0.375 Å) were constructed using 54 x 54 x 54 points for the box 
dimensions, and a total of 200 Lamarckian genetic algorithm runs were performed, 
using 2x107 evaluations. The systematic analysis of the different binding poses was 
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performed by clustering the results using a r.m.s.d. of 1.8 Å. The pose obtained 
manually was always within the two best poses found by AutoDock.  
Surface Plasmon Resonance 
Surface Plasmon Resonance (SPR) experiments were performed at 25 ºC using Biacore 
3000 (GE Healthcare). PBST (10 mM phosphate pH 7.4, 150 mM NaCl and 0.005% v/v 
surfactant P20) was used as running buffer for CM5 and CM4 experiments while HBS 
(10 mM HEPES pH 7.4, 150 mM NaCl) was used for HPA experiments. 
AcKDAlaDAlaOH and AcKDAlaDLac acid acetate (or Ac2KDAlaDAlaOH and 
Ac2KDAlaDLac acid acetate in early experiments) were diluted to 2 mg/mL in 10 mM 
phosphate pH 8 buffer and immobilized in separate flowcells of a CM5 sensor chip 
following amine coupling method according to the manufacturer’s instructions. 
Immobilization response was 166 RU and 196 RU for AcKDAlaDAlaOH (flow cell 2) 
and AcKDAlaDLac acid acetate (flow cell 3), respectively. Sensor chip flow cell 1 was 
activated, blocked and used as a reference surface. The same immobilization procedure 
was carried out on a CM4 chip. Immobilization response was 83 RU and 69 RU for 
AcKDAlaDAlaOH (flow cell 2) and AcKDAlaDLac acid acetate (flow cell 3), 
respectively. Sensor chip flow cell 1 was activated, blocked and used as a reference 
surface. Blank samples and concentration series were injected on CM5 and CM4 chips 
at a flow rate of 50 µL/min for 180 s and dissociation was registered for 180 s. Chip 
CM5 concentration series were 25, 50, 100, 150, 200 and 250 nM of vancomycin; 5, 10, 
15, 20, 25, 30 nM of teicoplanin and A40926; 0.5, 1.0, 2.0, 5.0, 7.5 and 10.0 nM of 
mideplanin and 1.0, 2.0, 5.0, 7.5, 10.0 and 12.5 nM of dalbavancin and MDL63,246. 
CM4 concentration series were 100, 200, 300, 400, 500 and 600 nM of vancomycin; 5, 
10, 15, 20, 25 and 30 nM of teicoplanin; 10, 20, 30, 40, 50 and 60 nM of mideplanin, 
dalbavancin and MDL63,264 and 20, 40, 80, 120, 160 and 200 nM of A40926. Finally, 
10 µM solutions of all glycopeptides were injected on a HPA chip at a flow rate of 5 
µL/min for 180 s and dissociation was registered for 180 s. Data processing and 
analysis was carried out using BiaEvaluation v.4.1.1 (GE Healthcare). All signals were 
blank substracted, reference corrected and globally adjusted to an adequate kinetic 
model to obtain binding parameters.  
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Fig. S1. TOCSY (60 ms) correlation of the W2 proton of teicoplanin upon addition of Ac2KDAlaDAlaOH. The chemical 
shift (> 12.5 ppm) indicates the presence of binding to the three-peptide and the existence of hydrogen bonding for this 
particular NH. The duplication of signals suggests the existence of two very similar bound species.  
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Fig. S2. The alternative secondary energy minimum of the complex of  MDL63246 with Ac2KDAlaDAlaOH. The key 
hydrogen bonds that replace the regular ones present in the global minimum are highlighted in green in the south part of the 
figure.  
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Fig. S3 Sensograms of Ac2KDAlaDAlaOH immobilized on a CM5 chip binding to vancomycin, mideplanin, teicoplanin, 
A40926, dalbavancin, and MDL63,246. 
 
